首页> 外文OA文献 >Response to Letter Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R 2 CHADS 2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts”

【2h】

Response to Letter Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R 2 CHADS 2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts”

机译：回应关于物品的信，“肾功能障碍是非衰弱性心房颤动患者中风和全身栓塞的预测因子：验证R 2 Chads 2指数在火箭AF中（rivaroxaban曾经每日，口服，直接因子XA抑制相比维生素K对患者预防心房颤动的卒中和栓塞试验的拮抗剂）和Atria（心房颤动的抗凝和危险因素）研究队列“

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Jonathan P. Piccini; Susanna R. Stevens; YuChiao Chang; Daniel E. Singer; Yuliya Lokhnygina; Alan S. Go; Manesh R. Patel; Kenneth W. Mahaffey; Jonathan L. Halperin; Günter Breithardt; Graeme J. Hankey; Werner Hacke; Richard C. Becker; Christopher C. Nessel; Keith A. A. Fox; Robert M. Califf;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts" [J] . Piccini Jonathan P., Stevens Susanna R., Chang YuChiao, Circulation: An Official Journal of the American Heart Association . 2013,第11期

机译：对有关“非瓣膜性房颤患者中风和全身性栓塞的预测指标：肾功能不全：ROCKET AF（Rivaroxaban每日一次，口服，直接因素）中的R（2）CHADS（2）指数的验证的答复Xa抑制与维生素K拮抗剂在房颤预防卒中和栓塞试验中的比较以及ATRIA（房颤的抗凝和危险因素）研究队列”
2. Letter by Apostolakis et al Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts" [J] . Apostolakis Stavros, Lane Deirdre A., Banerjee Amitava Circulation: An Official Journal of the American Heart Association . 2013,第11期

机译：Acostolakis等人关于文章的信，“肾功能障碍是非衰弱性心房颤动患者中风和全身栓塞的预测因子：验证R（2）牧草（2）指数在火箭AF中的指数（Rivaroxaban曾经每日，口服，与维生素K拮抗剂相比，直接因子XA抑制预防心房颤动中的中风和栓塞试验）和阿里亚（心房颤动的抗凝和危险因素）研究队列“
3. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: Analysis from the ROCKET AF trial (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) [J] . PatelM.R., HellkampA.S., LokhnyginaY., Journal of the American College of Cardiology . 2013,第6期

机译：非瓣膜性房颤患者停用利伐沙班与华法林相比的结果：ROCKET AF试验的分析（Rivaroxaban每日一次口服口服直接Xa抑制与维生素K拮抗作用相比较，以预防中风和房颤栓塞试验）
4. Risk Factors for Stroke in Chinese with Atrial Fibrillation: Case-control Study [C] . O.Y. Hu, Y.H. Sun, Z.Q. Zhou, World Congress on Cardiac Pacing and Electrophysiology . 2003

机译：心房颤动中文中风危险因素：案例控制研究
5. Editors Choice: Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding safety and tolerability study of four doses of AZD0837 vs. vitamin K antagonists [O] . Gregory Y.H. Lip, Lars H. Rasmussen, S. Bertil Olsson, -1

机译：编辑推荐：口服直接凝血酶抑制剂AZD0837用于预防非瓣膜性房颤患者的中风和全身性栓塞：四种剂量AZD0837和维生素K拮抗剂的随机剂量指导安全性和耐受性研究
6. Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) [O] . Patel Manesh R., Hellkamp Anne S., Lokhnygina Yuliya, 2013

机译：ROCKET AF试验对非瓣膜性房颤患者中止利伐沙班与华法林比较的结果（Rivaroxaban每日一次，口服，直接因子Xa抑制与维生素K拮抗剂的比较预防房颤的卒中和栓塞试验）

著录项

相似文献

相关主题

期刊订阅